TSE:RVX

Resverlogix Corp. (RVX.TO) Stock Forecast, Price & News

C$0.96

+0.05 (+5.49 %)

(As of 03/5/2021 03:59 PM ET)

Add

Compare

Today's Range

C$0.89

Now: C$0.96▼

C$0.96

50-Day Range

C$0.89

MA: C$0.93▼

C$1.02

52-Week Range

C$0.56

Now: C$0.96▼

C$1.52

Volume32,125 shs

Average Volume55,352 shs

Market CapitalizationC$224.63 million

P/E Ratio53.33

Dividend YieldN/A

BetaN/A

Resverlogix Corp. operates as a late-stage clinical biotechnology company. The company is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trials for patients with cardiovascular, chronic kidney, end-stage renal, neurodegenerative, fabry, peripheral artery, and other orphan diseases, as well as diabetes mellitus. Resverlogix Corp. is headquartered in Calgary, Canada.

Headlines

New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19
March 3, 2021 | finance.yahoo.com

Resverlogix Corp. (RVX.TO)
January 30, 2021 | uk.finance.yahoo.com

Resverlogix Reschedules Update Webcast and Conference Call
January 27, 2021 | finance.yahoo.com

Resverlogix Announces Update Webcast and Conference Call
January 19, 2021 | finance.yahoo.com

Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
January 12, 2021 | finance.yahoo.com

Resverlogix Announces Voting Results from the 2020 Meeting of Shareholders and Update on $13 Million Investment by Sheikh Abdulgader Aboud Baeshen
December 22, 2020 | finance.yahoo.com

Resverlogix Announces Apabetalone Treatment Prior to SARS-CoV-2 (COVID-19) Exposure Significantly Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
December 22, 2020 | finance.yahoo.com

What Type Of Shareholders Own The Most Number of Resverlogix Corp. (TSE:RVX) Shares?
December 11, 2020 | finance.yahoo.com

Resverlogix Announces Publication in High-impact, Peer-reviewed Journal, Clinical Epigenetics
November 12, 2020 | finance.yahoo.com

Resverlogix Reports Filing of New Intellectual Property on Key Renal Protection and Glucose Control Markers
November 2, 2020 | finance.yahoo.com

Zenith Confirms Interim Filings on SEDAR - Yahoo Finance
October 28, 2020 | finance.yahoo.com

Zenith Confirms Interim Filings on SEDAR
October 28, 2020 | finance.yahoo.com

A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms - GlobeNewswire
October 26, 2020 | globenewswire.com

A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms
October 26, 2020 | finance.yahoo.com

Resverlogix Announces Presentations at Leading Scientific Conferences Toronto Stock Exchange:RVX - GlobeNewswire
October 15, 2020 | globenewswire.com

Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet - GlobeNewswire
October 14, 2020 | globenewswire.com

Resverlogix Corp: Resverlogix Announces Conversion of US$12 Million Debenture Strengthening Balance Sheet
October 14, 2020 | finanznachrichten.de

Resverlogix Announces $13 Million Private Placement
October 8, 2020 | benzinga.com

Resverlogix Announces $13 Million Private Placement Toronto Stock Exchange:RVX - GlobeNewswire
October 6, 2020 | globenewswire.com

Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications - StreetInsider.com
October 5, 2020 | streetinsider.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:RVX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.resverlogix.com

Phone+1-403-2549252

Employees25

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio0.15

Quick Ratio0.05

Price-To-Earnings

Trailing P/E Ratio53.33

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowC$0.00 per share

Price / Cash Flow800.00

Book ValueC($0.23) per share

Price / Book-4.25

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares233,987,000

Market CapC$224.63 million

Next Earnings Date3/12/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.72 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Resverlogix Corp. (RVX.TO).

3.6 Community Rank

Outperform Votes
Resverlogix Corp. (RVX.TO) has received 310 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Resverlogix Corp. (RVX.TO) has received 118 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Resverlogix Corp. (RVX.TO) has received 72.43% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Resverlogix Corp. (RVX.TO) and other stocks. Vote “Outperform” if you believe RVX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RVX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Resverlogix Corp. (RVX.TO) does not currently pay a dividend.
Dividend Growth
Resverlogix Corp. (RVX.TO) does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Resverlogix Corp. (RVX.TO) insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Resverlogix Corp. (RVX.TO) is 53.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 31.26.
Price to Earnings Ratio vs. Sector
The P/E ratio of Resverlogix Corp. (RVX.TO) is 53.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 38.17.

See Top Rated MarketRank™ Stocks Here

C$0.96

+0.05 (+5.49 %)

(As of 03/5/2021 03:59 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive RVX News and Ratings via Email

Sign-up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.

Resverlogix Corp. (RVX.TO) (TSE:RVX) Frequently Asked Questions

What stocks does MarketBeat like better than Resverlogix Corp. (RVX.TO)?

Wall Street analysts have given Resverlogix Corp. (RVX.TO) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Resverlogix Corp. (RVX.TO) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Resverlogix Corp. (RVX.TO)'s next earnings date?

Resverlogix Corp. (RVX.TO) is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Resverlogix Corp. (RVX.TO).

How were Resverlogix Corp. (RVX.TO)'s earnings last quarter?

Resverlogix Corp. (RVX.TO) (TSE:RVX) released its quarterly earnings results on Monday, December, 14th. The biotechnology company reported ($0.03) EPS for the quarter.
View Resverlogix Corp. (RVX.TO)'s earnings history.

How has Resverlogix Corp. (RVX.TO)'s stock price been impacted by Coronavirus (COVID-19)?

Resverlogix Corp. (RVX.TO)'s stock was trading at C$1.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RVX shares have decreased by 6.8% and is now trading at C$0.96.
View which stocks have been most impacted by COVID-19.

Who are Resverlogix Corp. (RVX.TO)'s key executives?

Resverlogix Corp. (RVX.TO)'s management team includes the following people:

Mr. Donald J. McCaffrey, Co-Founder, Chairman, Pres, CEO & Sec.
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV, Chief Financial Officer
Mr. Kenneth Eugene Lebioda BA, Sr. VP of Bus. & Corp. Devel.
Dr. Michael Sweeney, Sr. VP of Clinical Devel. (Age 60, Pay $525.29k)
Dr. Ewelina Kulikowski, Sr. VP of R&D
Dr. Norman C.W. Wong B.Sc., FRCPC, M.Sc., B.Sc (Hon), M.Sc, M.D., FRCP(, Co-Founder, Chief Scientific Officer & Chairman of the Scientific Advisory Board
Mr. Paul Moon, VP of Investor Relations & Communications
Sarah Zapotichny, Director of Investor Relations & Corp. Communications
Dr. Jan O. Johansson, Sr. VP of Medical Affairs

Who are some of Resverlogix Corp. (RVX.TO)'s key competitors?

Some companies that are related to Resverlogix Corp. (RVX.TO) include Pharming Group (PHAR), Oxford Biomedica plc (OXB.L) (OXB), Sigilon Therapeutics (SGTX), Biotest Aktiengesellschaft (BIO), Ergomed (ERGO), Inventiva (IVA), Silence Therapeutics (SLN), Landos Biopharma (LABP), Novacyt (NCYT), Angion Biomedica (ANGN), Terns Pharmaceuticals (TERN), Pfenex (PFNX), NexImmune (NEXI), Decibel Therapeutics (DBTX) and Sensei Biotherapeutics (SNSE).
View all of RVX's competitors.

What other stocks do shareholders of Resverlogix Corp. (RVX.TO) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Resverlogix Corp. (RVX.TO) investors own include ProMetic Life Sciences (PLI), Aptose Biosciences (APTO), Oncolytics Biotech (ONC), (ATE), Radient Technologies (RTI), VentriPoint Diagnostics (VPT), Endocyte (ECYT), Allena Pharmaceuticals (ALNA), Catalyst Pharmaceuticals (CPRX) and Royalty Pharma (RPRX).

What is Resverlogix Corp. (RVX.TO)'s stock symbol?

Resverlogix Corp. (RVX.TO) trades on the Toronto Stock Exchange (TSX) under the ticker symbol "RVX."

How do I buy shares of Resverlogix Corp. (RVX.TO)?

Shares of RVX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Resverlogix Corp. (RVX.TO)'s stock price today?

One share of RVX stock can currently be purchased for approximately C$0.96.

How much money does Resverlogix Corp. (RVX.TO) make?

Resverlogix Corp. (RVX.TO) has a market capitalization of C$224.63 million.

How many employees does Resverlogix Corp. (RVX.TO) have?

Resverlogix Corp. (RVX.TO) employs 25 workers across the globe.

What is Resverlogix Corp. (RVX.TO)'s official website?

The official website for Resverlogix Corp. (RVX.TO) is www.resverlogix.com.

Where are Resverlogix Corp. (RVX.TO)'s headquarters?

Resverlogix Corp. (RVX.TO) is headquartered at 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada.

How can I contact Resverlogix Corp. (RVX.TO)?

Resverlogix Corp. (RVX.TO)'s mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The biotechnology company can be reached via phone at +1-403-2549252.

This page was last updated on 3/5/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here